High Bridge, NJ, United States of America

Claire Lankin

USPTO Granted Patents = 8 

 

Average Co-Inventor Count = 6.0

ph-index = 2

Forward Citations = 5(Granted Patents)


Company Filing History:


Years Active: 2008-2025

Loading Chart...
Loading Chart...
8 patents (USPTO):

Title: Claire Lankin: Innovator in Cardiometabolic Disease Treatment

Introduction

Claire Lankin is a prominent inventor based in High Bridge, NJ (US). She has made significant contributions to the field of medicine, particularly in the treatment of cardiometabolic diseases, kidney disease, and diabetes. With a total of 8 patents to her name, Lankin's work has the potential to impact many lives.

Latest Patents

Lankin's latest patents include innovative compounds that target various health issues. One of her notable inventions is related to natriuretic peptide receptor A agonists, which are useful for treating cardiometabolic diseases, kidney disease, and diabetes. This invention encompasses compounds of Formula I and their pharmaceutically acceptable salts or prodrugs. Additionally, she has developed compounds that alter bile acid levels, acting as Cyp8b1 inhibitors to prevent and treat diabetes and cardiovascular disease.

Career Highlights

Throughout her career, Claire Lankin has worked with leading pharmaceutical companies, including Merck Sharp & Dohme Corporation and Schering Corporation. Her expertise in drug development and innovative solutions has positioned her as a key player in her field.

Collaborations

Lankin has collaborated with notable professionals in her industry, including Craig D. Boyle and Samuel Chackalamannil. These partnerships have further enhanced her research and development efforts.

Conclusion

Claire Lankin's contributions to the medical field through her patents and collaborations highlight her dedication to improving health outcomes for patients with cardiometabolic diseases. Her innovative work continues to pave the way for advancements in treatment options.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…